Tenaya Therapeutics CEO to Present at Leerink Partners Healthcare Conference
Event summary
- Tenaya Therapeutics CEO Faraz Ali to participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026.
- Event scheduled for 1:00 pm ET and will be webcast live from Tenaya’s Investor Relations page.
- Archived replay available for 30 days post-conference.
- Tenaya focuses on gene therapies for heart disease, including TN-201 for HCM and TN-401 for ARVC.
The big picture
Tenaya Therapeutics’ participation in the Leerink Partners conference underscores its focus on advancing gene therapies for heart disease. The event provides a platform to showcase its pipeline, including TN-201 and TN-401, amid growing interest in curative treatments for genetic cardiac conditions. Tenaya’s ability to translate its scientific advancements into marketable therapies will be critical in sustaining investor support.
What we're watching
- Pipeline Progress
- How Tenaya’s clinical-stage candidates TN-201 and TN-401 advance in development.
- Market Positioning
- Whether Tenaya can differentiate itself in the competitive gene therapy space.
- Investor Sentiment
- The impact of CEO Faraz Ali’s presentation on investor confidence and stock performance.
Related topics